Compare
INVO Fertility, Inc. vs Encision Inc vs Beyond Air, Inc. vs Cerenome, Inc.
| Latest fiscal year | INVO Fertility, Inc. IVF | Encision Inc ECIALast annual report: year ended 2025-03-31 | Beyond Air, Inc. XAIR | Cerenome, Inc. CNSY |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-03-31 | 2026-03-31 | 2025-12-31 |
| Revenue | $6.84M | $6.56M | $7.68M | $5.21M |
| Revenue growth (YoY) | +4.7% | -0.5% | +107.3% | -10.5% |
| Gross margin | n/a | 53.6% | 3.3% | n/a |
| Operating margin | -105.8% | -2.6% | -378.2% | -293.5% |
| Net margin | -340.9% | -3.4% | -433.0% | -429.4% |
| Net income | -$23.32M | -$220.2K | -$33.25M | -$22.39M |
| EPS (Diluted) | -$214.64 | -$0.02 | -$4.01 | -$0.29 |
| Operating cash flow | -$7.01M | -$54.9K | -$18.14M | -$20.77M |
| Free cash flow | -$7.06M | -$109.4K | -$19.17M | -$20.84M |
| Cash & equivalents | n/a | $257.4K | $6.74M | $4.26M |
| Total assets | $20.22M | $3.67M | $35.38M | $16.32M |
| Total liabilities | $13.00M | $2.02M | $29.18M | $12.33M |
| Shareholders' equity | $7.22M | $1.65M | $6.13M | $4.00M |
| Return on year-end equity | -322.8% | -13.3% | -542.8% | -560.2% |
| Shares outstanding | 477.4K | 11.88M | 11.79M | 138.68M |
Revenue, most recent five fiscal years
| Fiscal year | INVO Fertility, Inc. | Encision Inc | Beyond Air, Inc. | Cerenome, Inc. |
|---|---|---|---|---|
| Latest | $6.84M Ended 2025-12-31 | $6.56M Ended 2025-03-31 | $7.68M Ended 2026-03-31 | $5.21M Ended 2025-12-31 |
| 1 year earlier | $6.53M Ended 2024-12-31 | $6.59M Ended 2024-03-31 | $3.71M Ended 2025-03-31 | $5.82M Ended 2024-12-31 |
| 2 years earlier | $3.02M Ended 2023-12-31 | $7.35M Ended 2023-03-31 | $1.16M Ended 2024-03-31 | $4.91M Ended 2023-12-31 |
| 3 years earlier | n/a | $7.67M Ended 2022-03-31 | n/a | n/a |
| 4 years earlier | n/a | $7.54M Ended 2021-03-31 | n/a | n/a |